Physician profile
Grant Olson
NPI 1467423087
$1,139.46
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $846 · 2020: $293.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $265.23 | 2019-2020 | |
| Glaxosmithkline, LLC. | $247.21 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $128.11 | 2019-2020 | |
| Optinose US, INC. | $111.44 | 2019 | |
| Grifols USA, LLC | $84.93 | 2019-2020 | |
| Genzyme Corporation | $61.98 | 2019-2020 | |
| Csl Behring | $55.00 | 2020 | |
| Pfizer INC. | $54.06 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $39.27 | 2019 | |
| Pharming Healthcare, INC. | $25.84 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.50 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $17.47 | 2019 | |
| Genentech USA, INC. | $14.24 | 2019 | |
| Circassia INC. | $14.18 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grant Olson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.